When does lurbinectedin’s full efficacy typically show up?
In clinical use, lurbinectedin’s best (full) response is generally assessed over the first several treatment cycles rather than immediately after the first dose. For solid tumors treated with lurbinectedin, response timing is typically based on imaging and tumor-response criteria performed at scheduled intervals during therapy, meaning the “full” efficacy often becomes clear after early-cycle reassessments.
What determines how quickly patients see a “full” response?
The timing depends on several factors:
- Tumor type and disease setting (for example, heavily pretreated vs. earlier lines)
- Baseline tumor burden and how quickly it can shrink
- Treatment schedule and when imaging happens relative to starting therapy
- Whether the patient’s response is complete vs. partial (complete responses usually take longer to declare than early partial changes)
How are responses measured in practice?
“Full efficacy” in oncology trials is usually not based on symptoms alone. It is determined using imaging-based response assessments (like RECIST-style criteria), done at protocol-defined timepoints. Those scheduled assessments are why clinicians typically only describe the degree of response after the early rounds of treatment.
If you mean “time to best response” specifically
If you want the exact “time to best response” for lurbinectedin (e.g., median time and range), I can give it, but I’d need the specific study context (indication and trial name, since timing can differ by dataset and protocol). If you share whether you mean small cell lung cancer or another indication, I can narrow it to the right evidence.